Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC versus placebo for new-onset CLAD after lung transplantation
ACTRN12616000338460Phase 2Recruiting
- Sponsor
- The University of Queensland
- Start
- Apr 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of allogeneic bone marrow-derived mesenchymal stromal cells in chronic lung allograft dysfunction (CLAD) (2 arms), sponsored by The University of Queensland. Primary endpoint: Progression-free survival. Started Apr 2017; status: recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
chronic lung allograft dysfunction (CLAD)
Beyond the preview
Go deeper on ACTRN12616000338460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000338460.